A retinal prosthetic device for the blind and nearly blind is awaiting FDA approval for the U.S. market, according to a report by the Wall Street Journal.
The device, called the Argus II and developed by Los Angeles-based medical device company Second Sight Medical Products, is already available in Europe. It implants electrodes in the retina of visually-impaired persons suffering from retinitis pigmentosa or macular degeneration, and uses video-capturing glasses to send images to the brain.
Second Sight has spent $200 million developing the product, half of which came from investors and the rest through federal grants.
Medical Device Tax Gathers $97M From Revenue in January
Sightpath Medical to Mobilize Femtosecond Laser for Cataract Surgery
The device, called the Argus II and developed by Los Angeles-based medical device company Second Sight Medical Products, is already available in Europe. It implants electrodes in the retina of visually-impaired persons suffering from retinitis pigmentosa or macular degeneration, and uses video-capturing glasses to send images to the brain.
Second Sight has spent $200 million developing the product, half of which came from investors and the rest through federal grants.
More Articles on Medical Devices:
Zimmer's 4Q Profits Drop 2.4% to $153MMedical Device Tax Gathers $97M From Revenue in January
Sightpath Medical to Mobilize Femtosecond Laser for Cataract Surgery